USD
$0.00
(0.00%
)At Close (As of Sep 26, 2025)
-
Market Cap
-
P/E Ratio
-
EPS
$9.99
52 Week High
$0.00
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Total Assets | $717K |
Total Current Assets | $457K |
Cash And Cash Equivalents At Carrying Value | $284K |
Cash And Short Term Investments | $284K |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $260K |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $146K |
Other Non Current Assets | - |
Total Liabilities | $3.9M |
Total Current Liabilities | $3.9M |
Current Accounts Payable | $651K |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $0 |
Capital Lease Obligations | - |
Long Term Debt | - |
Current Long Term Debt | $1.8M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | - |
Other Current Liabilities | $489K |
Other Non Current Liabilities | - |
Total Shareholder Equity | -$3.2M |
Treasury Stock | - |
Retained Earnings | -$13M |
Common Stock | - |
Common Stock Shares Outstanding | $9.1M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company based in Tel Aviv-Yafo, Israel, specializing in the development of innovative intranasal drug formulations aimed at addressing critical emergency medical conditions. With a groundbreaking approach to drug delivery, Nasus Pharma is leveraging its proprietary technology to enhance treatment efficacy and patient compliance. The company's pipeline reflects a commitment to improving outcomes in urgent care scenarios, positioning it as a potential leader in the niche market of intranasal therapeutics.